New Zealand-based AFT Pharmaceuticals (NZX: AFT) has announced the signing of a further new licence agreements for the intravenous dose form of its Maxigesic pain relief medicine as it continues to build momentum in its international business. Maxigesic is a patented combination of paracetamol and ibuprofen.
The privately owned Swiss pharmaceutical company Labatec has licensed the intravenous form, Maxigesic IV, in Switzerland. Labatec and AFT are aiming for registration and launch of the medicine - a treatment for mild to moderate pain for use post-operatively in hospitals when patients cannot take a medicine orally – in the next 12 to 18 months.
Additionally, Pharma Bavaria has extended its existing Maxigesic IV licence agreement in Latin America to include Argentina and Paraguay in addition to the licences already agreed with AFT for the medicine in Bolivia, Chile, Columbia, Ecuador, Peru, Uruguay. The agreements build on launches of Maxigesic IV since the start of the year in the Netherlands, Denmark, Sweden, Norway, and Finland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze